You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Conversion therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Cancer Trial in Nanjing (Cadonilimab+mFOLFIRINOX)

Not yet recruiting
  • Pancreatic Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Nov 23, 2023

Gastric Cancer Trial (Envolimab, Fuquinitinib, Oxaliplatin)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Jun 13, 2023

Locally Advanced Pancreatic Cancer Trial in Guangzhou (Sulfatinib, Serplulimab, Albumin-paclitaxel)

Not yet recruiting
  • Locally Advanced Pancreatic Cancer
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Aug 10, 2023

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Trial (XELOX combined with Fruquintinib and Sintilimab)

Not yet recruiting
  • Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
  • XELOX combined with Fruquintinib and Sintilimab
  • (no location specified)
Oct 17, 2023

Squamous Cell Carcinoma of Head and Neck Trial in Hangzhou (Toripalimab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Hangzhou, Zhejiang, China
    Department of Medical Onocology, First Affiliated Hospital of Zh
Oct 7, 2023

Pulmonary Tumor, Advanced Cancer, Locally Advanced Cancer Trial in Shanghai (Surgery)

Recruiting
  • Pulmonary Neoplasm
  • +2 more
  • Surgery
  • Shanghai, Shanghai, China
    Ruijin hospital, Shanghai JiaoTong University School of Medicine
Dec 15, 2022

Immunotherapy in Conversion Therapy of Unresectable Gastric

Recruiting
  • Unresectable Gastric Cancer
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Nov 8, 2022

    Unresectable Lung Non-Small Cell Carcinoma Trial (serplulimab plus chemo as conversion treatment)

    Not yet recruiting
    • Unresectable Lung Non-Small Cell Carcinoma
    • serplulimab plus chemotherapy as conversion treatment
    • (no location specified)
    Apr 27, 2023

    Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma Trial in Nanjing (Tislelizumab, 5-FU, cis Platinum)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Locally Advanced Carcinoma
    • Nanjing, Jiangsu, China
      Jiangsu Provincial People's Hospital
    Jul 19, 2022

    Gastric Cancer Trial (Camrelizumab Nab-Paclitaxel S-1)

    Not yet recruiting
    • Gastric Cancer
    • Camrelizumab Nab-Paclitaxel S-1
    • (no location specified)
    Jun 20, 2022

    Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation Trial in Nanjing (Tislelizumab, Paclitaxel, Carboplatin)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • +2 more
    • Nanjing, Jiangsu, China
      Jiangsu Cancer Institute & Hospital
    May 24, 2022

    Gastric Cancer Trial (Disitamab Vedotin, Sintilimab, S-1)

    Not yet recruiting
    • Gastric Cancer
    • Disitamab Vedotin
    • +3 more
    • (no location specified)
    Nov 17, 2022

    Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • HAIC
    • +8 more
    • Quanzhou, Fujian, China
    • +1 more
    Jan 26, 2023

    A Small-sample, Real-world Study of Sintilimab Plus

    Recruiting
    • Colorectal Cancer
    • Sintilimab ，bevcizumab/cetuximab，XELOX
    • Xi'an, Shanxi, China
      Yang Jianjun
    Sep 14, 2022

    Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

    Recruiting
    • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
    • +2 more
    • Beijing, Beijing, China
    • +1 more
    Nov 21, 2023

    Gastric Cancer Trial in Zhengzhou (fruquintinib + sintilimab + SOX)

    Not yet recruiting
    • Gastric Cancer
    • fruquintinib + sintilimab + SOX
    • Zhengzhou, Henan, China
    • +1 more
    Dec 15, 2021

    Colorectal Cancer Trial in Shanghai (Fruquintinib+mFOLFOX6/FOLFIRI)

    Recruiting
    • Colorectal Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Aug 23, 2023

    Gastric Adenocarcinoma Trial in Beijing (Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1)

    Recruiting
    • Gastric Adenocarcinoma
    • Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jan 27, 2022

    Gastric Cancer Trial in Tianjin (Comparing Hyperthermic Intraperitoneal Chemotherapy, Paclitaxel, S1)

    Recruiting
    • Gastric Cancer
    • Comparing Hyperthermic Intraperitoneal Chemotherapy
    • +2 more
    • Tianjin, Tianjin, China
      Department of Gastrointestinal Medical Oncology, Tianjin Medical
    Jan 26, 2022

    Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • TACE
    • +8 more
    • Quanzhou, Fujian, China
    • +3 more
    Jan 29, 2023

    Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable Trial in Tianjin (tislelizumab+ Paclitaxel + Cisplatin)

    Recruiting
    • Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
    • Unresectable
    • tislelizumab+ Paclitaxel + Cisplatin
    • Tianjin, Tianjin, China
      Hongjing Jiang
    Jul 7, 2022

    Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Trial in Tianjin

    Recruiting
    • Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute & Hospital
    Nov 16, 2022

    Hepatocellular Carcinoma Trial in Shanghai (Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE)

    Enrolling by invitation
    • Hepatocellular Carcinoma
    • Lenvatinib 4 MG Oral Capsule [Lenvima]
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Zhongshan Hospital
    Sep 23, 2021

    PDO Models and Clinical Outcomes in Gastric Cancer

    Recruiting
    • Gastric Cancer
    • Tumor biopsy
    • Shanghai, Shanghai, China
      Zhongshan Hospital Fudan University
    Jan 10, 2022

    Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Drug-eluting bead transarterial chemoembolization (DEB-TACE),

    Recruiting
    • Hepatocellular Carcinoma Non-resectable
    • Drug-eluting bead transarterial chemoembolization (DEB-TACE)
    • Conventional transarterial chemoembolization (cTACE)
    • Guangzhou, Guangdong, China
      the Second Affiliated Hospital of Guangzhou Medical University
    Jul 8, 2021